FOSTER CITY, Calif. ( TheStreet) -- Gilead Sciences (GILD) reported positive results Tuesday from the first in a series of late-stage studies to support the regulatory approval of its hepatitis C pill sofosbuvir.
If approved, sofosbuvir will be the main component of the first all-oral combination regimen to treat hepatitis C, eliminating the need for traditional injectable drugs.
Gilead expects to seek approval of sofosbuvir in the middle of 2013.
This first phase III study, dubbed POSITRON, examined a 12-week course of therapy consisting of sofosbuvir (formerly known as GS-7977) plus the immune booster ribavirin. The study enrolled patients with genotype 2 or 3 hepatitis C who were not candidates for treatment with interferon, the injectable drug commonly used today.Genotype 2/3 is less common in the U.S. than genotype 1 but still represents about one-third of all hepatitis C cases worldwide. Seventy-eight percent of patients treated with sofosbuvir and ribavirin for 12 weeks achieved a sustained virologic response (SVR), the medical term that denotes a cure for hepatitis C. By comparison, none of the patients treated with a placebo in the study achieved a cure. The 78% cure rate for sofosbuvir plus ribavirin met but didn't exceed Wall Street expectations, said ISI Group analyst Mark Schoenebaum, in an email to clients. "As Gilead is a very high expectation stock, we would not expect the stock to move up much at all today, and could even trade down a bit," Schoenebaum writes. Gilead shares were down less than 1% to $75 in early Tuesday trading. Two additional phase III studies of sofosbuvir in genotype 2/3 patients are underway with results expected in the first quarter 2013. Phase III studies of sofosbivir in the more prevalent genotype 1 hepatitis C patient population are also being conducted, with results expected next year. Gilead most promising and anticipated hepatitis C regimen consists of sofosbuvir, a so-called "nuc" polymerase inhibitor plus GS-5885, an NS5A inhibitor. Abbott Labs (ABT) has begun phase III studies of its own all-oral hepatits C regimens. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV